Tauriga Sciences Inc. Acquires Equity Stake in Israeli Biotechnology Firm that Develops Drugs Based on Cannabinoid Molecules

NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has acquired an equity stake in an Israeli biotechnology firm that develops drugs based on Cannabinoid molecules. The Company believes that this equity stake is potentially complementary to its own ongoing Pharmaceutical development efforts (also involving Cannabinoid molecules).        

Link to original post